Smarter Planet: Life Sciences


Published on

At the center of smarter life sciencesis an increasingly more networked operation focused on the end patient. The result is also a safe, effective and valued treatment solution targeted at the patient.

Published in: Business
1 Comment
  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Smarter Planet: Life Sciences

  1. 1. George Mattathil -5/17/2011Let’s Build A Smarter Planet:What will it mean for Life Sciences? © 2010 IBM Corporation
  2. 2. The reality of living in a globally integrated world is upon us. Safety, quality, efficacy of products is challenged more than ever before Outdated and inefficient (drug) research and development (R&D) has contributed to expiring patents, dry pipelines and cost Generic alternatives abound as pricing pressures increase Globalization efforts and the new economic environment have constrained resourcesThe world is connected:economically, socially and technically. © 2010 IBM Corporation
  3. 3. The need for progress is clear. 50% 65.2 billion of patients drop out of their Dollars invested in US pharma treatment within the first and biotech R&D in 2008. Only 4 year.20% of prescriptions go truly innovative products were unfilled in hard economic times delivered in the same period.2 and 30% of prescriptions are not refilled.1 90% 74 billion of drugs work in only Dollars US lost due to 30-50% of people3 a 10% counterfeit drug supply41 ―ECONOMIC CRISIS : Pharma Sales Will Drop As Patients Cut Back on Prescriptions‖2 R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges, March 10, 20093 ―Demolished - the myth that allows drugs giants to sell more‖. , The Independent, Dec. 8, 2003.4 ―Partnership for Safe Medicines Arms Public Against Counterfeit Drugs‖ Dec. 2, 2008 and IBM analysis © 2010 IBM Corporation
  4. 4. The opportunity for progress is clear.Better compliance with treatment More innovative discovery & developmentSmarter Life Sciences: Smarter Life Sciences:Merit Foundation Ecole Polytechnique Federale de LausanneA Netherlands based non-commercial, international A major Swiss research institute harnesses themedical organization accesses thousands of power of supercomputers to model the human brain,anonymous patient records and monitors patients’ speeding the search for causes and cures ofprogress and benchmark responses to treatment neurological and psychiatric diseases with the abilityagainst information about others to run simulations in close to real timeImproved patient insights Reduced risk from counterfeitsSmarter Life Sciences: Smarter Life Sciences:Metabasis therapeutics, Inc. GSMS, Inc.A biopharmaceutical company in the U.S. A small U.S. wholesale pharmaceuticals distributor,speeds time to market for metabolic- and liver- contract manufacturer and packaging companydisease therapies deploys a pharmaceutical track and trace solution ahead of the competitionThe demand for change is strongThe 2008 Global CEO Study: ―The Enterprise of the Future‖ © 2010 IBM Corporation
  5. 5. The demand for change is strong. LIFE SCIENCES CEO’S GLOBAL CEO’S8 in 10Life Sciences leadersanticipate substantialchange ahead.22%Gap between envisionedchange and past successat managing it.Change Needed © 2010 IBM Corporation
  6. 6. For life sciences companies, this means leading in the face ofglobal challenges brought on by three key drivers while overcomingtwo key inhibitors.DRIVERS INHIBITORSBETTER UNDERSTANDING OF THE COST AND REVENUE PRESSURESFUNDAMENTALS OF THE DISEASE GROWING RAPIDLYPredictability of a treatment’s efficacy and Restructured business models tosafety will drive improved outcomes streamline overall operations including strategic outsourcing, partnering and turning to emerging marketsPRODUCT MODELS MOVE TO BIOLOGICSDrugs targeted at a defined populationas well as disease-modifying and preventative REGULATORY, POLITICAL AND SOCIETALin nature PRESSURES INTENSIFYING Legislation is forcing investments in supply chain traceability and promotionalDISRUPTIVE SCIENCE AND spending analysisTECHNOLOGY EMERGINGIncreased use of medical imaging andbiomarkers in the move to targeted treatmentsand personalized medicine © 2010 IBM Corporation
  7. 7. A smarter system forges partnerships in order to delivertreatment solutions which are targeted at the individual patient. Smarter Discovery & DevelopmentCollaboration with  People and the Other life sciences organization companies Smarter life  Technology Biotech sciences  Processes Medical device organization Smarter Smarter and diagnostic Sales & Supply manufacturers Marketing Chain  Enhanced Contract communication with organizations end consumer Academic centers  Compliance Hospitals / clinics  Patient persistence Patients  Consumer insights Network of smart partners Patient / consumer insights © 2010 IBM Corporation
  8. 8. It’s a new world—and life sciences organizations are key playersin an economy that demands increased value, safer solutions, betteroutcomes, sustainability and accountability. INNOVATE OPERATE EFFECTIVELY Develop new business models to Align and optimize processes to compete more effectively. Fuel support patient centered healthcare innovation in R&D and drive delivery and patient safety to drive greater discovery productivity. better outcomes and an enhanced LIFE experience. SCIENCES ENGAGE Enable life sciences to take an active role in empower a healthier society and patients by collaborating to improve breakthrough therapies. © 2010 IBM Corporation
  9. 9. + + = An opportunity for life science organizations to think and act in new ways.Innovate Operate Effectively Engage © 2010 IBM Corporation
  10. 10. Smart life sciences:Innovate.SMART IS SMART ISImproving the efficiency of drug discovery Reducing attrition rates and costsand development through to reformulation during discovery by use of highof existing drug products to extend performance computing.product life cycle.SMART IS SMART ISFueling clinical innovation with much Integrating all relevant data, reproducingmore processing power while the control principles of a biologicaldecreasing operating costs. system and simulating how it will respond. © 2010 IBM Corporation
  11. 11. Smart life sciences:Operate Effectively.SMART IS SMART ISCombating risk by building Automating baseline activities in theintelligence into both products supply chain increases responsiveness toand packaging. free up time for employees to manage critical exceptions and focus on higher value activities.SMART IS SMART ISAutomatically analyzing and correlating Enabling research beyond the currentinformation from multiple sources to ―trial, file, and archive‖ data usage modelidentify areas of risk and regulatory through clinical & safety data accessiblecompliance exposures. across studies. © 2010 IBM Corporation
  12. 12. Smart life sciences:Engage.SMART IS SMART ISDriving more innovation and short term Identifying actions to stem the impactrevenues through collaboration. of chronic diseases like diabetes, heart disease or stroke by modeling disease progression.SMART IS SMART ISMonitoring impending disasters and Building in interconnectivity across aproactively responding so supply of network to provide a hands-on view oftargeted treatment is available immediately. the entire supply chain for all parties. © 2010 IBM Corporation
  13. 13. Smart life sciences:Innovate. Engage.Ecole Polytechnique Federale de Lausanne (EPFL): Merit Foundation: developed METEOR – Measurement ofEmbarked on Project Blue Brain, a joint research venture Efficacy of Treatment in the Era of Outcome inwith IBM to create a model of the fundamental building Rheumatology – an Internet-based solution that willblocks of the human brain, unprecedented in its scope – revolutionize and improve patient treatment. Clinicians nowultimately generating functional models for 10,000 have access to thousands of anonymous patient records,morphologically complex neurons. covering several countries and many hospitals; they can learn from one another on the best treatment for patients.Innovate.Engage.National Genographic: created a DNA analysis repository that lets researchers and scientists analyze gathered geneticdata and identify patterns among the samples. Private citizens can also contribute samples to the DNA repository, hosted inan IBM DB2® data server, and view personalized ancestral migration profiles on the organization’s Web site. This hasEstablishes one of the largest centralized collections of genetic information, increasing collaboration among scientistsand researchers. © 2010 IBM Corporation
  14. 14. Operate Effectively.Metabasis Therapeutics: Highly-accurate, first-of-a- Golden State Medical Supply, Inc. (GSMS):kind simulation software significantly lowers drug Implemented the Pharma Track & Trace Solution usingdiscovery time and costs by eliminating 80% of the two-dimensional barcodes, radio frequencycompounds to be synthesized and tested in the lab.1 identification (RFID) and other sensors to track product movements. Puts GSMS in an advantageous competitive position by making it one of the first distributors to comply with the new regulations.Fujita Pharmaceutical LTD, Co. : Improved its total Bilcare Limited: Developed a Track-and-Traceproject management capabilities. The new solution Solution framework to seamlessly integrated into anyhelps the company minimize out-of-stock instances supply chain system, providing real-time productby consistently managing sales, production, authentication. The technology helps detectpurchases of raw materials and accounting through a counterfeit goods, potentially saving millions of livessingle system. © 2010 IBM Corporation
  15. 15. Smart life sciences: IBM Research ProjectsNew Intelligence Research Example Smart Work Research ExampleProtecting the privacy of biometric data by Leveraging Blue Gene for large scale simulationcreating an anonymous biometrics recognition in the drug discovery process.system that scales to large populations.Dynamic Infrastructure Research ExamplesAutomatically analyzing and correlating Building governance and maintenance tools toinformation from multiple sources to identify support benefit configuration, research, andareas of risk and regulatory compliance exposures. correction processes. © 2010 IBM Corporation
  16. 16. At the center of smarter life sciencesis an increasingly morenetworked operation focused on the end patient. IMPROVING COLLABORATING operations internally with other biophamra, academia MEASURING your progress SHARING  IMPROVED PATIENT and plan patient insights INSIGHTS  REDUCED RISK FROM COUNTERFEITS COMPLYING with regulations  BETTER COMPLIANCE WITH TREATMENT  MORE INNOVATIVE MONITORING UNDERSTANDING DISCOVERY & and responding fundamental of the DEVELOPMENT to signals disease CONVERGING INTEGRATING across industries all relevant data both internally and externallyThe result is also a safe, effective and valued treatmentsolution targeted at the patient. © 2010 IBM Corporation
  17. 17. The imperative for life sciences today is clear.INNOVATE OPERATE EFFECTIVELY ENGAGE Develop strategies in  Optimize core systems and  Interconnect researchers support of advanced infrastructure to reduce costs from academic, industry and therapies and technologies, and to more flexibly service regulators to bolster product such as gene and cell new business demands pipelines therapies and  Use technology to  Bridge internal silos with nanotechnology communicate, share information better collaboration tools and Fuel drug discovery by and assist in decision-support infrastructures investing in innovative  Employ a fact-based,  Build an integrated network decision-making quantitative risk management of manufacturing, and approaches approach in the supply chain distribution partners Maximize development with and by building intelligence into the integration of modeling products and packaging and simulation into new clinical trial programs Use social networking to connect globally to gather insights to fuel innovation © 2010 IBM Corporation
  18. 18. IBM’s solution strategy is aligned with the needsof all stakeholders of the life sciences companies. LIFE SCIENCES SYSTEMS ARE FOCUSED ON… IBM IS INVESTING IN…  Systems biology Innovate and thrive  Nanotechnology  Smarter Analytics & Information Agenda  Clinical decision support systems  Customer segmentation / e-detailing  Business process modeling, analytics and performance management  Life Sciences Hub  Biopartnering strategy  Interoperability Streamline and transform  Medical home: Patient-centered collaborative care  Patient portals  Collaborative platforms & tools  Risk Modeling  Universal Data Model/Warehouse Collaborate and empower  The New Pharma Commercial Model  Marketing and Sales  Regulatory Compliance  Pharmacoviligence  Content Management  Pharma Track and Trace © 2010 IBM Corporation
  19. 19. We’ve only just begunto uncover what is possible ona smarter planet. The world will continue to become smaller, flatter and smarter. We are moving into the age of the globally integrated and intelligent economy, society and planet. To thrive in a smarter planet, life sciences organizations need to transform so they are more streamlined internally and collaborating effectively externally to deliver more innovative products. There’s no better time to start building a smarter life sciences industry to provide more patient-centric treatment for society.Let’s work together to drivereal progress in our world. © 2010 IBM Corporation
  20. 20. Trademarks and notes IBM Corporation 2009  IBM, the IBM logo and are registered trademarks, and other company, product or service names may be trademarks or service marks of International Business Machines Corporation in the United States, other countries, or both. A current list of IBM trademarks is available on the Web at ―Copyright and trademark information‖ at  Adobe, the Adobe logo, PostScript, the PostScript logo, Cell Broadband Engine, Intel, the Intel logo, Intel Inside, the Intel Inside logo, Intel Centrino, the Intel Centrino logo, Celeron, Intel Xeon, Intel SpeedStep, Itanium, IT Infrastructure Library, ITIL, Java and all Java-based trademarks, Linux, Microsoft, Windows, Windows NT, the Windows logo, and UNIX are trademarks or service marks of others as described under ―Special attributions‖ at:  Other company, product and service names may be trademarks or service marks of others.  References in this publication to IBM products or services do not imply that IBM intends to make them available in all countries in which IBM operates. © 2010 IBM Corporation